Syra Health Corp-A 2025年季度报告

For the quarterly period endedMarch 31,2025 SYRA HEALTH CORP. (Exact Name of Registrant as Specified in its Charter)Delaware(State or other jurisdiction ofincorporation or organization)1119 Keystone Way N. #201,Carmel,Indiana (463)345-8950 (Registrant’s telephone number, including area code) Not applicable(Former name, former address and former fiscal year, if changed since last report) reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.Large accelerated filerAccelerated filer Item 1.Legal Proceedings Item 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity SecuritiesItem 3.Defaults Upon Senior SecuritiesItem 5.Other Information 2 “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these termsor other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates andprojections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. Wemay not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or eventscould differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and ourforward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertaintiesinherent in our statements regarding:●our projected financial position and estimated cash burn rate; ●competitive pressures including offerings and pricing;●our ability toestablish and maintain strategic relationships;●undetected errors or similar problems in our software products;●compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcareindustry; 20252024CASH FLOWS FROM OPERATING ACTIVITIES$(472,265)$(1,447,050)Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation, stock options Changes in operating assets and liabilities:Accounts receivable(265,029)Accounts receivable, related party-Other current assets65,775Right-of-use asset244,419 Operating lease liability(244,419)Net cash provided by/(used in) operating activities158,231CASH FLOWS FROM INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds received on exercise of warrants14,800Repayments on notes payable(77,851)Net cash provided by/(used in) financing activities(63,051) Interest paid $-$NON-CASH INVESTING AND FINANCING ACTIVITIES:Conversion of Class B common stock to Class A common stock$2,333$ Note 1 –Nature of Business and Significant Accounting PoliciesNature of Business government agencies, integrated health networks, managed care entities and pharmaceutical manufacturers. On March 11, 2022, theCompany redomiciled to Delaware. The Company’s corporate office is located in Carmel, Indiana. Basis of PresentationThe accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally Exchange Commission (“SEC”) on March 11, 2025. Certain information and footnote disclosures normally included in the financialstatements prepared in accordance with U.S. GAAP have been omitted from this report on Form 10-Q pursuant to the rules and regulations of the SEC.Results for the interim periods in this report are not necessarily indicative of future financial results and have not been audited by our statements include all adjustments necessary to present fairly our interim financial statements as of March 31, 2025, and for the threemonths ended March 31, 2025 and 2024. These adjustments are of a normal recurring nature and consistent with the adjustments recorded to prepare the annual audited financial statements as of December 31, 2024. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions thatmay affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financialstatements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these $1,351,337and $1,032,827cash in excess of FDIC insured limits at March 31, 2025 and December 31, 2024, respectively. TheCompany has not experienced any losses in such accounts. Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:-Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.Level 2 inputs to the valuation methodology include quoted prices for similar assets